
**Cardiovascular implants — Cardiac
valve prostheses —**

**Part 2:
Surgically implanted heart valve
substitutes**

Implants cardiovasculaires — Prothèses valvulaires —

Partie 2: Prothèse valvulaires implantées chirurgicalement





COPYRIGHT PROTECTED DOCUMENT

© ISO 2021

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

	Page
Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Abbreviations	3
5 Fundamental requirements	4
6 Device description	4
6.1 General	4
6.2 Intended use	4
6.3 Design inputs	4
6.3.1 Operational specifications	4
6.3.2 Performance specifications	4
6.3.3 Packaging, labelling, and sterilization	5
6.4 Design outputs	5
6.5 Design transfer (manufacturing verification/validation)	5
6.6 Risk management	6
7 Design verification and validation	6
7.1 General requirements	6
7.2 <i>In vitro</i> assessment	6
7.2.1 General	6
7.2.2 Test conditions, sample selection, and reporting requirements	6
7.2.3 Material property assessment	6
7.2.4 Hydrodynamic performance assessment	6
7.2.5 Structural performance assessment	7
7.2.6 Design- or procedure-specific testing	8
7.2.7 Device MRI compatibility	8
7.2.8 Simulated use	8
7.2.9 Human factors/usability assessment	8
7.2.10 Implant thrombogenic and haemolytic potential assessment	8
7.3 Preclinical <i>in vivo</i> evaluation	8
7.3.1 General	8
7.3.2 Overall requirements	8
7.3.3 Methods	9
7.3.4 Test report	10
7.4 Clinical investigations	11
7.4.1 General	11
7.4.2 Study considerations	12
7.4.3 Study endpoints	13
7.4.4 Ethical considerations	14
7.4.5 Pivotal studies: Distribution of subjects and investigators	14
7.4.6 Statistical considerations including sample size and duration	15
7.4.7 Patient selection criteria	16
7.4.8 Valve thrombosis prevention	17
7.4.9 Clinical data requirements	17
Annex A (informative) Surgical heart valve substitute hazard analysis example	22
Annex B (informative) <i>In vitro</i> procedures for testing unstented or similar valves in compliant chambers	24
Annex C (informative) Preclinical <i>in vivo</i> evaluation	26
Annex D (informative) Description of the surgical heart valve substitute and system	29